top of page

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company is targeting CBP/p300 just stared phase 1 data at World Lung

3 hours ago

1 min read

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.

https://vimeo.com/1231273651?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections

From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections

PureTech, which is built on a hub and spoke model of creating biotechs, recently received positive end of phase 1 feedback from FDA on its galectin-9 targeting cancer medicine from Gallop Oncology

PureTech, which is built on a hub and spoke model of creating biotechs, recently received positive end of phase 1 feedback from FDA on its galectin-9 targeting cancer medicine from Gallop Oncology

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page